Why BGPT?
logo

Author Claim Review

Examine the evidence base and provenance of specific claims made by authors or groups.Know what the science actually supports before you trust the answer.

Press Enter ↡ to review


     Quick Explanation



    Eva Rohde (ORCID 0000-0001-8692-886X) is a senior translational cell-therapy and extracellular-vesicle researcher with h-index 35, 154 works, and ~29,042 citations, co-authoring landmark ISEV standards (MISEV2018, ~11,099 cites; MISEV2023, ~4,679 cites) . The two French-language records in the narrower author profile (h-index 0) reflect entity-resolution noise, not her true output.


     Long Explanation



    Evidence basis. The narrower profile ("E. Rohde": 2 papers, 0 citations) conflicts sharply with the OpenAlex-verified Eva Rohde profile (A5024617009, ORCID 0000-0001-8692-886X): 154 works, 29,042 citations, h-index 35, and citations rising monotonically to 4,527 in 2026 β€” a strongly still-active trajectory . Her two signature contributions are (1) a 2005 first-author Stem Cells paper showing blood monocytes can mimic endothelial progenitor cells, critically reframing EPC assays , and (2) co-developing human platelet lysate to replace fetal bovine serum for clinical-scale MSC expansion . She has consistently shaped EV-therapy standardization (ISEV position papers, MSC-sEV definitions, manufacturing reviews) .

    Limitations. Most top papers are consensus/position statements where Rohde is one of dozens of co-authors, so per-author contribution is unattributable; citation counts inflate via guideline adoption rather than independent empirical discovery. First-author empirical work is concentrated 2005–2010 in the Graz/Paracelsus groups. The 2-paper/h-0 profile is an entity-resolution artifact (French-language patent-style records), a known OpenAlex name-disambiguation blind spot β€” conclusions drawn from it alone would be misleading.



    Feedback:    

    Updated: November 01, 2026

     BGPT Author Review



    Scientific Quality

    80%

    Strong translational record: first-author mechanistic paper (EPC mimicry), widely adopted MSC culture protocol, and co-authorship on field-standard ISEV guidelines. Docked points because most high-impact output is multi-author consensus work where individual contribution is hard to isolate, and no Nobel-tier or paradigm-creating single-author breakthroughs are evident.



    Communication Quality

    80%

    Co-authorship of MISEV guidelines and manufacturing reviews demonstrates ability to write clear, actionable standards adopted globally; some works are dense consensus documents, which is inherent to the genre.



    Author Novelty

    70%

    The 2005 monocyte/EPC mimicry paper was a genuinely critical corrective to a then-popular EPC narrative, and platelet-lysate MSC expansion was a practical innovation; later work is largely standardization and consolidation rather than new conceptual ground.



    Scientific Rigor

    80%

    Participation in MISEV rigor initiatives and careful falsification of EPC assay assumptions indicate methodological discipline; rigorous translational/GMP framing throughout. Some early EPC-era work was later substantially reinterpreted by the field, reflecting era-specific measurement limitations.

     Hypothesis Graveyard



    That the 2-paper, h-index-0 profile represents a distinct junior researcher: refuted by ORCID matching to the senior, highly cited Eva Rohde; it is citation-database entity fragmentation.


    That EPCs isolated by LDL-uptake/lectin binding are true endothelial progenitors: substantially undermined by Rohde's own first-author mimicry evidence and subsequent field consensus.

     Science Art


    Author Review: Eva Rohde Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT